A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Latest Information Update: 04 Jun 2025
At a glance
- Drugs ELVN-001 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms ENABLE
- Sponsors Enliven Therapeutics
Most Recent Events
- 14 May 2025 According to an Enliven Therapeutics media release, data from this trial will be presented at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually. Updated data will be presented during an oral presentation at the conference on Friday, June 13, at 5 p.m. CEST/11 a.m. ET. Enliven management will host a webcast and conference call to discuss the data on Friday, June 13, at 7:30 p.m. CEST/1:30 p.m. ET.
- 14 May 2025 Results presented in the Enliven Therapeutics Media Release
- 13 Mar 2025 According to an Enliven Therapeutics media release, the company plans to report additional data from the ongoing Phase 1a/b trial in the middle of 2025.